| Trial ID: | L1387 |
| Source ID: | NCT02266394
|
| Associated Drug: |
Mesenchymal Stem Cell
|
| Title: |
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Disease|Chronic Kidney Disease
|
| Interventions: |
DRUG: Mesenchymal stem cell|PROCEDURE: Mesenchymal stem cell delivery with stent placement
|
| Outcome Measures: |
Primary: Change in Kidney function, Renal Tissue oxygenation, 3 months|Safety of Mesenchymal stem cell infusion, Number of patients with tissue injury markers, 2 years | Secondary: Decrease in Kidney inflammation, Venous and tissue biomarkers of inflammation, 3 months
|
| Sponsor/Collaborators: |
Sponsor: Mayo Clinic | Collaborators: University of Mississippi Medical Center|University of Alabama at Birmingham
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
42
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2014-10-21
|
| Completion Date: |
2020-09-25
|
| Results First Posted: |
|
| Last Update Posted: |
2021-01-27
|
| Locations: |
University of Alabama, Birmingham, Alabama, 35294, United States|Mayo Clinic, Rochester, Minnesota, 55902, United States|University of Mississippi, Jackson, Mississippi, 39216, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02266394
|
